|
|
(HealthNewsDigest.com) – COSTA MESA, Calif. – (January 12, 2015) – Each year, the number of Americans who support the legalization of medical marijuana continues to inch higher. According to Gallup, roughly 51 percent of adults today support the legalization, compared to only 34 percent who supported the legalization a decade ago. As the number of supporters for its legalization grow, so too do the number of people seeking relief from a broad range of ailments using cannabis-derived therapeutics.
“We are excited about the possibilities of cannabis-based treatments,” explains John Hollister, the chief executive officer of NEMUS Bioscience, Inc. (OTC QB: NMUS). “Our mission is to discover, develop and commercialize effective prescriptive cannabis-derived medicines and enhance the quality-of-life of patients that have significant unmet medical needs.”
Through its partnership with the University of Mississippi, NEMUS is focusing on the development of early stage cannabinoid product candidates coupled with innovative, alternative delivery methods that could have beneficial effects across a spectrum of diseases, including these medical ailments:
1. Glaucoma. According to the Glaucoma Research Foundation, there are 2.2 million Americans with the disease, including more than 120,000 who are blinded by it. The disease is associated with an increased fluid pressure inside the eyes that causes irreversible damage to the optic nerve Smoking marijuana is known to be effective in temporarily lowering pressure within the eye, however smoking can harm the optic nerve by lowering systemic blood pressure. NEMUS’ data suggests that focused ocular delivery of a proprietary formulation of THC can directly deliver the active ingredient in cannabis, to all three chambers of the eye. This novel delivery approach is expected to deliver the therapy only to the eye and bypass the general circulation thus avoiding the issues seen with smoking cannabis. This first-in-class therapy candidate may also help heal and/or prevent damage to the eye’s optic nerve.
2. Optic-nerve disorders. While glaucoma is one optic-nerve disorder, there are others, including those associated with diabetes (diabetic neuropathy), retinitis pigmentosa, and macular degeneration. Cannabis-based treatments may bring relief to those suffering from a variety of optic-nerve disorders.
3. Spasticity associated with Multiple sclerosis (MS). MS is a progressively debilitating disorder of the central nervous system that affects more than 2.3 million people worldwide, according to the National Multiple Sclerosis Society. Controlled studies have found that cannabis-based treatments can help manage disease-associated symptoms such as pain, spasms and spasticity.
4. Anxiety. Anxiety refers to a constellation of both mental and physiological phenomena that can result in a person’s conscious state of worry over a future unwanted event, or fear of an actual situation. Anxiety and fear are closely related. The National Institute of Mental Health reports there are a wide variety of anxiety disorders, including obsessive-compulsive disorder, panic disorder, and post traumatic stress disorder. Some have found that cannabis-based treatments can help to provide the calm that those with these conditions need in order to help them resume a more normal life.
5. Epilepsy. According to the Centers for Disease Control and Prevention, one out of every 26 people in the country will be diagnosed with epilepsy in their lifetime. The condition, which is characterized by recurrent seizures, is believed to be helped by the use of cannabis-based treatments.
“There are millions of people who may benefit from using cannabis-basted treatments,” added Hollister. “We are excited at the potential to help bring millions of people the relief they haven’t been able to find elsewhere. When it comes to developing cannabis-based treatments we are just getting started, and our hopes are to become a major player in developing pharmaceuticals that deliver the medical benefits of cannabis with greater predictability, less person-to-person variability and fewer adverse effects than smoking or ingesting ray herbs.”
About NEMUS Bioscience, Inc.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for global markets with significant unmet medical needs. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.
For more information on NEMUS Bioscience, Inc., visit their site at:www.nemusbioscience.com.
###
For advertising/promotion contact Mike McCurdy: 877-634-9180 or [email protected] … We have over 7,000 journalists as subscribers.